For the quarter ending 2025-09-30, PGEN had $562K increase in cash & cash equivalents over the period. -$29,458K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -146,344 | -80,795 |
| Depreciation and amortization | 803 | 1,259 |
| Loss (gain) on disposals of assets, net | 0 | -14 |
| Impairment of goodwill | 0 | 3,907 |
| Impairment of other noncurrent assets | 0 | 0 |
| Loss on reclassification of cumulative foreign currency translation adjustments | 0 | - |
| Change in fair value of warrant liabilities | -111,502 | -28,021 |
| Amortization of discounts on investments, net | 318 | 1,174 |
| Stock-based compensation expense | 4,388 | 4,315 |
| Shares issued as payment for services | 0 | 527 |
| Accretion of debt discount and amortization of deferred financing costs | 72 | - |
| Deferred income taxes | 0 | 0 |
| Trade | 253 | -599 |
| Other | 279 | 4 |
| Inventory | 2,948 | - |
| Prepaid expenses | 1,872 | -910 |
| Other assets | 167 | 215 |
| Accounts payable | 1,548 | 684 |
| Accrued compensation and benefits | 4,967 | 1,662 |
| Other accrued liabilities | 1,232 | 5,378 |
| Deferred revenue | -1,657 | -291 |
| Lease liabilities | 94 | -99 |
| Settlement and indemnification accruals | 0 | 0 |
| Other long-term liabilities | 163 | - |
| Net cash used in operating activities | -29,069 | -35,302 |
| Purchases of investments | 145,271 | 38,875 |
| Sales and maturities of investments | 82,274 | 62,448 |
| Purchases of property, plant and equipment | 389 | 1,588 |
| Proceeds from sale of assets | 0 | 0 |
| Net cash (used in) provided by investing activities | -63,386 | 21,985 |
| (payments) proceeds from issuance of common stock, net of issuance costs | 0 | -355 |
| Proceeds from long-term debt, net of issuance costs | 93,472 | - |
| Payments to taxing authorities in connection with shares directly withheld from employees | 0 | 1,776 |
| Proceeds from stock option exercises | 839 | 223 |
| Cash payment for performance stock units | -1,304 | - |
| Payment of issuance costs related to series a preferred stock | 0 | 537 |
| Net cash provided by financing activities | 93,007 | -2,445 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 10 | 5 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | 562 | -15,757 |
| Cash and cash equivalents at beginning of period | 29,517 | - |
| Cash and cash equivalents at end of period | 14,322 | - |
PRECIGEN, INC. (PGEN)
PRECIGEN, INC. (PGEN)